{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:19:51Z","timestamp":1789809591244,"version":"4.0.1"},"reference-count":51,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y\u2010XD2019\u2010124"],"award-info":[{"award-number":["Y\u2010XD2019\u2010124"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","award":["202002030205"],"award-info":[{"award-number":["202002030205"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Extranodal natural killer\/T\u2010cell lymphoma, nasal\u2010type (ENKTL) is a distinct subtype of non\u2010Hodgkin lymphoma and most of the patients presented localized disease. Combined modality therapy (CMT), namely chemotherapy combined with radiotherapy, has been recommended for patients with early\u2010stage ENKTL. However, the optimal CMT has not been fully clarified. This study reports the efficacy and toxicity of sequential P\u2010GEMOX (pegaspargase, gemcitabine and oxaliplatin) and radiotherapy in a large Chinese cohort comprising of 202 patients diagnosed with early\u2010stage ENKTL from six medical centers. The observed best overall response rate was 96.0% and 168 (83.2%) patients achieved complete remission. With a median follow\u2010up of 44.1\u00a0months, the 3\u2010year progression\u2010free survival (PFS) and overall survival (OS) were 74.6% and 85.2%, respectively. Multivariate analysis suggested that extensive primary tumor (PFS, hazard ratio [HR] 3.660, 95% CI 1.820\u20137.359,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt; \u20090.001; OS, HR 3.825, 95% CI 1.442\u201310.148,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.007) and Eastern Cooperative Oncology Group performance status \u2265 2 (PFS, 3.042, 95% CI 1.468\u20136.306,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.003; OS, HR 3.983, 95% CI 1.678\u20139.457,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.02) were independent prognostic factors for survival outcomes. Among the established prognostic models for ENKTL, the nomogram\u2010revised risk index model had optimal prognostic risk stratification ability (PFS,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001; OS,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and relatively balanced population distribution. The adverse events of this CMT were well\u2010tolerated and manageable. In conclusion, sequential P\u2010GEMOX and radiotherapy showed favorable efficacy with acceptable toxicity, and could be an effective treatment option for early\u2010stage ENKTL patients.\n                  <\/jats:p>","DOI":"10.1002\/ajh.26335","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T09:17:50Z","timestamp":1630055870000},"page":"1481-1490","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Sequential\n                    <scp>P\u2010GEMOX<\/scp>\n                    and radiotherapy for early\u2010stage extranodal natural killer\/\n                    <scp>T\u2010<\/scp>\n                    cell lymphoma: A multicenter study"],"prefix":"10.1002","volume":"96","author":[{"given":"Yuchen","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyun","family":"Ma","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Lymphadenoma and Head &amp; Neck Medical Oncology Fujian Provincial Cancer Hospital &amp; Institute  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4958-2489","authenticated-orcid":false,"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Hematology, Lymphoma Research Center Peking University Third Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuerong","family":"Shuang","sequence":"additional","affiliation":[{"name":"Department of Lymphohematology and Oncology Jiangxi Cancer Hospital  Nanchang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology First Affiliated Hospital of Guangxi Medical University  Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2732-9354","authenticated-orcid":false,"given":"Bingzong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology Second Affiliated Hospital with Suzhou University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-7026","authenticated-orcid":false,"given":"Panpan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Hematology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoguang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lymphadenoma and Head &amp; Neck Medical Oncology Fujian Provincial Cancer Hospital &amp; Institute  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Lymphadenoma and Head &amp; Neck Medical Oncology Fujian Provincial Cancer Hospital &amp; Institute  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Lymphoma Research Center Peking University Third Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Lymphohematology and Oncology Jiangxi Cancer Hospital  Nanchang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology First Affiliated Hospital of Guangxi Medical University  Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology Second Affiliated Hospital with Suzhou University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-3282","authenticated-orcid":false,"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0706-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00386"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn147"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12039"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02916-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12148"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2573"},{"key":"e_1_2_9_9_1","unstructured":"National Comprehensive Cancer Network.Guidelines: T\u2010Cell Lymphomas. Version 1.2021 \u2010 October 5 2020."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0687-0"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-791418"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx684"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.06.080"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2395-y"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1108415"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21256"},{"issue":"3","key":"e_1_2_9_17_1","first-page":"1359","article-title":"Down\u2010regulation of intracellular reactive oxygen species attenuates P\u2010glycoprotein\u2010associated chemoresistance in Epstein\u2010Barr virus\u2010positive NK\/T\u2010cell lymphoma","volume":"11","author":"Nam YS","year":"2019","journal-title":"Am J Transl Res"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05694.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-018-0334-8"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307454"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287"},{"key":"e_1_2_9_22_1","first-page":"134","article-title":"Efficacy and survival in newly diagnosed advanced Extranodal natural killer\/T\u2010cell lymphoma: a randomized, controlled, multicenter and open\u2010Labled study with Ddgp regimen versus SMILE regimen","author":"Wang X","year":"2019","journal-title":"Blood"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8643"},{"key":"e_1_2_9_24_1","first-page":"132","article-title":"P\u2010Gemox regimen (Pegaspargase, gemcitabine, oxaliplatin) for extranodal natural killer cell lymphoma: 10\u2009years\u2019 real\u2010world clinical experience from China","author":"Yan G","year":"2018","journal-title":"Blood"},{"key":"e_1_2_9_25_1","first-page":"134","article-title":"Clinical outcome of an multicentre, randomized, phase II clinical trial for patients with extranodal NK\/T cell lymphoma treated by P\u2010Gemox or Aspametdex","author":"Huang H\u2010Q","year":"2019","journal-title":"Blood"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.01.009"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0791-3"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00533-1"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.1384"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8592"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8295"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2137-6"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27752"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3327"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2016.1264163"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.10.011"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04036-z"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2214"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0559-7"},{"issue":"15","key":"e_1_2_9_43_1","first-page":"2","article-title":"Sintilimab for relapsed\/refractory (r\/r) extranodal NK\/T cell lymphoma (ENKTL): extended follow\u2010up on the multicenter, single\u2010arm phase II trail (ORIENT\u20104). Meeting abstract","volume":"38","author":"Li JY","year":"2020","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00331-3"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2056"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.44"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639336"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902803669"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-354142"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435024"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.02.005"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010637"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26335","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T19:41:08Z","timestamp":1692992468000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/ajh.26335"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26335","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"2021-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}